Oresund Pharma acquires the international rights outside the US for Therakind’s oncology and autoimmune product, Jylamvo®
London, England – May 2024 – Therakind Limited (“Therakind”), a specialty pharmaceutical company focused on developing and delivering niche medicines for difficult-to-treat patient groups, today announces that Oresund Pharma ApS (‘Oresund’), a Danish speciality pharmaceutical company, has acquired all non-US rights for Jylamvo®, Therakind’s oncology and autoimmune product, for an upfront payment and downstream royalites.
Dr Susan Conroy, CEO of Therakind, said: “We have an excellent working relationship with Oresund, who has been responsible for the distribution of Jylamvo® in the Nordic countries for over three years, and we are delighted to leave Jylamvo® in their hands. Oresund will now serve the entire European market and plan to expand the potential market beyond Europe. This divestment is part of a strategic approach to enable Therakind to focus on the core research and development of our proprietary nasal delivery portfolio.”
Patrick Cohn, CEO & Co-founder of Oresund, added: “Jylamvo® is a high-quality pharmaceutical product with significant growth potential in the European market. We have worked closely with Therakind in the distribution of Jylamvo® across multiple territories for several years, and we are now proud to officially incorporate this medicine into our product portfolio. While our initial focus is on the European market, we are actively exploring opportunities to expand distribution into additional regions in the near future.”
Jylamvo® is a palatable novel methotrexate 2mg/ml oral solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and for the maintenance treatment of acute lymphoblastic leukaemia (ALL), and for adult severe psoriasis and severe psoriatic arthritis. Jylamvo® has a marketing authorisation that allows it to be sold throughout the European Economic Area and was the first oral liquid formulation of methotrexate to be authorised across Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
For more information, please contact:
Therakind Ltd
Dr Susan Conroy, Chief Executive Officer
Tel: ++44 (0) 208 346 603
Email: info@therakind.com
Website: www.therakind.com
About Therakind Limited
Therakind is a specialty pharmaceutical company with a proprietary and partnered pipeline focused on improving medicine adherence through more patient-friendly dosing options. We have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to incorporate the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. To date, we have developed and obtained marketing authorisations for three products and our intranasal device for the delivery of a dry powder drug formulation, DriDose®, is available for co-development.
To find out more, please visit www.therakind.com
About Oresund Pharma ApS
Oresund Pharma is a privately owned specialty pharmaceutical company headquartered in Denmark, committed to bringing value-added treatment solutions to the market. We focus on delivering products that stand out in the competitive pharmaceutical landscape by prioritizing patient needs and addressing critical unmet medical requirements internationally.
With a comprehensive organizational structure, Oresund efficiently manages all aspects of commercial operations, including sales and marketing, warehousing and logistics, finance, regulatory affairs, and pharmacovigilance. Our goal is to ensure that every activity we undertake adds value to our partners, suppliers, customers, and most importantly, the patients we serve.
To find out more, please visithttps://www.oresundpharma.com